Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.61 |
| ▸ | NOS3 | P29474 | 5/20 | 0.56 |
| ▸ | NOS2 | P35228 | 5/20 | 0.56 |
| ▸ | NOS1 | P29475 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30935767 | 1.00 | DYRK1A (0.63) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL10461111 | 0.97 | DYRK1A (0.61) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL30337203 | 0.95 | DYRK1A (0.70) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL29733143 | 0.90 | DYRK1A (0.60) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL4411668 | 0.90 | DYRK1A (0.60) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL1836488 | 0.88 | DYRK1A (0.58) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL29432628 | 0.88 | DYRK1A (0.58) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL15649966 | 0.88 | DYRK1A (0.63) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL1159709 | 0.86 | DYRK1A (0.56) | DYRK1AMKNK1MKNK2NOS3NOS2 | |
| SCHEMBL17632269 | 0.86 | DYRK1A (0.54) | DYRK1AMKNK1MKNK2NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004052880-A1 | PYRIDINE DERIVATIVES AS JNK INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | WO | claimed |
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| EP-1109545-A4 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004052880-A1 | PYRIDINE DERIVATIVES AS JNK INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052880-A1 | PYRIDINE DERIVATIVES AS JNK INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | WO | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | DYRK1A 916/4885MKNK1 4549/4885MKNK2 4624/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | DYRK1A 1974/4885MKNK1 3596/4885MKNK2 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.